Recent developments include management changes, capital raises, clinical trial milestones, patent approvals, and strategic evaluations amid operational uncertainties.

• Indaptus Therapeutics entered a $6 million securities deal and appointed David Lazar as Co-CEO and Chairman in late 2025 [N3].
• The company raised $5.7 million through convertible promissory notes and warrants in mid-2025 [N5].
• Indaptus secured $2.3 million through convertible promissory notes and warrants in a funding round in June 2025 [N6].
• The company launched a Phase 1 study to evaluate Decoy20 in combination with Tislelizumab in March 2025 [N7].
• Indaptus enrolled over 20 patients in the Phase 1 trial of Decoy20, achieving a key clinical milestone by March 2025 [N8].
• The company secured new patent approvals in China, Japan, and Israel for its Decoy platform targeting HIV and HBV treatment in early 2025 [N8].
• Indaptus expanded the Decoy20 clinical trial to Canada and received clinical trial authorization from Health Canada in February 2025 [N8].
• The company posted a narrower loss in Q2 2025, reflecting some operational progress [N4].
• Significant management changes occurred in early 2026, including resignations of Co-CEO David Lazar and Chief Scientific Officer Michael Newman [S2].
• Indaptus discontinued enrollment in its Combination Study and currently has no active clinical development programs as of mid-2026 [S2].
• The company is evaluating strategic alternatives for its Decoy20 program and broader business operations amid substantial uncertainty [S2].

The company has achieved key clinical milestones, including patient enrollment in Phase 1 trials and international patent approvals, which demonstrate progress in its novel immunotherapy platform. Expansion of clinical trials to new geographies and ongoing strategic evaluations may provide pathways to development or partnerships. Recent capital raises through convertible notes and securities deals provide some financial resources to support operations and development activities. The company's patented platform targeting significant diseases like cancer, HIV, and HBV could offer differentiated therapeutic options if development advances.

Indaptus faces substantial operational and financial risks, including recurring net losses, liquidity challenges, and substantial doubt about its ability to continue as a going concern. The discontinuation of enrollment in clinical trials and absence of active development programs highlight development uncertainties. Significant management turnover and ongoing strategic evaluations introduce organizational instability. Dilution risks from convertible preferred stock and potential adverse effects from macroeconomic conditions and reverse stock split may impact shareholder value. The company's early-stage status and lack of commercial products increase the risk of failure to achieve regulatory approvals or market acceptance.

Indaptus Therapeutics' moat is primarily based on its novel and patented immunotherapy platform targeting cancer and viral diseases, including HIV and HBV. The company holds patent approvals in key international markets such as China, Japan, and Israel, which provide some intellectual property protection. However, as a clinical-stage biotechnology company with no approved products or commercial revenues, its competitive advantage is contingent on successful clinical development and regulatory approvals, which remain uncertain. The company's early-stage status and financial constraints limit its current market position and operational scale.

• Financial and Liquidity Risks: The company has incurred significant net losses and cash outflows, raising substantial doubt about its ability to continue as a going concern. Liquidity depends on successful capital raises and strategic transactions.
• Clinical Development Risks: Discontinuation of enrollment in clinical trials and absence of active programs create uncertainty about future product development and regulatory approvals.
• Management and Organizational Risks: Recent significant changes in executive management and board composition may disrupt operations and strategic initiatives during the transition period.
• Dilution and Control Risks: Issuance of convertible preferred stock could lead to significant dilution and concentration of voting control, reducing existing stockholders' influence.
• Market and Regulatory Risks: Macroeconomic conditions, public health crises, and regulatory uncertainties may negatively impact operations, capital access, and development timelines.
• Reverse Stock Split Risks: The reverse stock split may not proportionally increase stock price, could reduce liquidity, and may result in odd lot holdings with higher transaction costs.

• Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy platform.
• All product candidates are in preclinical or early clinical development stages; none have received marketing approval or are commercialized.
• The company has discontinued enrollment in its Combination Study and currently has no active clinical development programs.
• Research and development expenses are a significant portion of operating expenses, primarily related to contract research organizations (CROs) and contract manufacturing organizations (CMOs).
• The company has accrued expenses for manufacturing, preclinical studies, and clinical trial activities based on estimates of services received.
• Indaptus has launched a Phase 1 study to evaluate Decoy20 in combination with Tislelizumab and has enrolled over 20 patients in this trial, achieving a key clinical milestone.
• The company has secured patent approvals in China, Japan, and Israel for its Decoy platform targeting HIV and HBV treatment.
• Indaptus has expanded its Decoy20 clinical trial to Canada and received clinical trial authorization from Health Canada for this expansion.
• Significant management changes occurred recently, including the appointment and subsequent resignation of Co-CEO David Lazar and other executive officers, with ongoing transitions in management and board composition.
• The company entered a $6 million securities deal and raised additional funds through convertible promissory notes and warrants in multiple rounds totaling several million dollars.
• Indaptus has increased its authorized common stock to 1 billion shares and implemented a 1-for-28 reverse stock split to enhance Nasdaq compliance and attract investors.
• The company reported a net loss of approximately $1.79 million for the quarter ended June 30, 2026, with basic and diluted EPS of -$0.02 per share.
• As of June 30, 2026, Indaptus held approximately $7.55 million in cash and equivalents, with a current ratio of 2.34 and a cash ratio of 15.59, indicating liquidity.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and cash outflows.
• Indaptus is evaluating strategic alternatives for its Decoy20 program and broader business operations, including potential transactions, collaborations, or acquisitions.
• The company’s future direction and viability are subject to substantial uncertainty, with no current active clinical programs and reduced development activities pending financing or strategic decisions.
• Significant dilution risk exists due to the issuance of preferred stock convertible into a large number of common shares, which would grant effective voting control to a major shareholder.
• The company’s business operations are exposed to risks from macroeconomic conditions, public health crises, and regulatory uncertainties.
• The reverse stock split may not increase stock price proportionally and could reduce liquidity and market capitalization.
• The company’s research and development expenses are expected to decrease in the short term due to discontinued enrollment in clinical trials.